Advertisement

Topics

Nabriva Therapeutics Company Profile

21:37 EDT 20th September 2017 | BioPortfolio

Headquartered in Vienna, Nabriva Therapeutics is engaged in the discovery and development of innovative antibacterial agents addressing unmet medical need in the hospital and community setting. The company has two compounds currently in clinical trials and expects to have a third compound enter clinical trials later this year. The lead compound, BC-3205, is a parenterally and orally available pleuromutilin which is first in class and has significant market potential in multiple indications (eg. SSSI & CAP). All of Nabriva's programs are derived from compounds generated in-house through discovery activity and the company maintains an ongoing effort in medicinal chemistry.


News Articles [1550 Associated News Articles listed on BioPortfolio]

Nabriva Therapeutics Announces Positive Phase III Results for Pneumonia Treatment

NewsLefamulin also met the primary endpoints for the European Medicines Agency (EMA) of non-inferiority.Contributed Author:&n

Nabriva's pneumonia drug succeeds in late-stage trial, shares soar

(Reuters) - Nabriva Therapeutics Plc shares more than doubled in premarket trading on Monday after the company said its experimental antibiotic for community-acquired bacterial pneumonia met the main...

STAT Plus: Nabriva novel antibiotic meets goals in late-stage bacterial pneumonia study

Nabriva Therapeutics (NBRV) took a big risk pushing its novel antibiotic, lefamulin, into a late-stage clinical trial in patients with hospital-acquired pneumonia without any prior clinical data. On M...

Nabriva Therapeutics: Buy The Secondary Offering

Nabriva Therapeutics: One Of The Biggest Binary Events Of September

Nabriva Therapeutics (NBRV) Investor Presentation - Slideshow

Nabriva Therapeutics Reports First Quarter 2017 Financial Results

VIENNA, Austria and KING OF PRUSSIA, Pa., May 10, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development ...

Nabriva Therapeutics Announces Webcast of Analyst & Investor Day on June 19, 2017

VIENNA, Austria and KING OF PRUSSIA, Pa., June 05, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and developme...

Clinical Trials [117 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1144 Associated Companies listed on BioPortfolio]

Nabriva Therapeutics

Headquartered in Vienna, Nabriva Therapeutics is engaged in the discovery and development of innovative antibacterial agents addressing unmet medical need in the hospital and community setting. Th...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

Click Therapeutics, Inc.

Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeutics™ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...

More Information about "Nabriva Therapeutics" on BioPortfolio

We have published hundreds of Nabriva Therapeutics news stories on BioPortfolio along with dozens of Nabriva Therapeutics Clinical Trials and PubMed Articles about Nabriva Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Nabriva Therapeutics Companies in our database. You can also find out about relevant Nabriva Therapeutics Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Prostate Cancer
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...


Corporate Database Quicklinks



Searches Linking to this Company Record